Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT (RTEP4)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study of the modification of the fixation(binding) of Fluoro-2-deoxy-D-glucose (FDG), fluoro-misonidazole (FMISO) and 3'deoxy-3-fluoro-thymidine deoxy-3-fluoro-thymidine (FLT) measured in tomography by broadcast(emission,issue) of positrons (PET) at patients before and in the course of exclusive radiotherapy or concomitant radiochemotherapy for primitive bronchial cancer.
This protocle allows to study the simultaneous variations of the metabolism, the hypoxie and the cellular proliferation by PET SCAN at 5 patients reached(affected) by a primitive bronchial cancer in the course of exclusive radiotherapy for primitive bronchial cancer not small cell lung.
The investigators are also going to study several scenarii of optimization of the radiotherapy according to the variations of the tumoral metabolism, the hypoxie and the cellular proliferation measured in the course of radiotherapy (theoretical study on console using the scanner and the various examinations).
| Condition |
|---|
|
Bronchial Neoplasms Carcinoma, Non-Small-Cell Lung |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Study of the Modification of the Fixation of FDG, F-Miso and FLT Measured in PET/CT at Patients Before and in the Course of Exclusive Radiotherapy or Concomitant Radiochemotherapy for Primitive Bronchial Cancer |
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Diagnosed patients with non-small-cell lung carcinoma
Inclusion Criteria:
- patients with non-small-cell lung carcinoma hitologicaly proved
- Candidate patients in a treatment with aim guardian by exclusive thoracic radiotherapy or of concomitant radiochemotherapy (tumoral dose superior to 60 Gy) ( n=5 ).
- Measurable tumor according to the criteria of evaluation RECIST
Exclusion Criteria:
- Histology other one than primitive bronchial cancer not in small cells lung
- The patients for whom no tumoral target is assessable (forgiveness completes after first chemotherapy, operated patients).
- Patients for whom a radiotherapy with curative aim is not indicated (tumoral extension, metastases, general state, co-morbidity).
- Patient having benefited from an examination PET in the FDG with in more than 4 weeks and for which a new PET in the FDG is not necessary with in the framework of its disease
Contacts and Locations| France | |
| Centre Henri Becquerel | |
| Rouen, Hate Normandie, France, 76000 | |
| Principal Investigator: | GUERNOU Mohamed, MD | CHBecquerel |
| Study Director: | VERA Pierre, MD phD | CHBecquerel |
More Information
No publications provided
| Responsible Party: | Mohamed GUERNOU MD, Centre Henri Becquerel |
| ClinicalTrials.gov Identifier: | NCT01261585 History of Changes |
| Other Study ID Numbers: | CHB 08-01 |
| Study First Received: | December 15, 2010 |
| Last Updated: | December 15, 2010 |
| Health Authority: | France: Institutional Ethical Committee |
Keywords provided by Centre Henri Becquerel:
|
Positron-Emission Tomography PET Scan FDG FLT |
FMISO Non-Small-Cell Lung Carcinoma chemo-Radiation Oncology SUV |
Additional relevant MeSH terms:
|
Bronchial Neoplasms Neoplasms Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Bronchial Diseases Respiratory Tract Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Carcinoma, Bronchogenic Lung Diseases |
ClinicalTrials.gov processed this record on May 19, 2013